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Background: Current tools for diagnosing latent TB infection (LTBI) detect immunological memory of past
exposure but are unable to determine whether exposure is recent. We sought to identify a whole-blood
transcriptome signature of recent TB exposure.
Methods: We studied household contacts of TB patients; healthy volunteers without recent history of TB exposure;
and patients with active TB. We performed whole-blood RNA sequencing (in all), an interferon gamma release assay
(IGRA; in contacts and healthy controls) and PET/MRI lung scans (in contacts only). We evaluated differentially-
expressed genes in household contacts (log2 fold change ≥1 versus healthy controls; false-discovery rate < 0.05);
compared these to differentially-expressed genes seen in the active TB group; and assessed the association of a
composite gene expression score to independent exposure/treatment/immunological variables.
Results: There were 186 differentially-expressed genes in household contacts (n = 26, age 22–66, 46% male) compared
with healthy controls (n = 5, age 29–38, 100% male). Of these genes, 141 (76%) were also differentially expressed in
active TB (n = 14, age 27–69, 71% male). The exposure signature included genes from inflammatory response, type I
interferon signalling and neutrophil-mediated immunity pathways; and genes such as BATF2 and SCARF1 known to be
associated with incipient TB. The composite gene-expression score was higher in IGRA-positive contacts (P = 0.04) but
not related to time from exposure, isoniazid prophylaxis, or abnormalities on PET/MRI (all P > 0.19).
Conclusions: Transcriptomics can detect TB exposure and, with further development, may be an approach of value for
epidemiological research and targeting public health interventions.
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Following exposure to and infection with tuberculosis
(TB) many individuals enter a state of latent TB infection
(LTBI) [1, 2]. An estimated 25% of the world’s population
has LTBI, with the highest prevalence found in the WHO© The Author(s). 2020 Open Access This artic
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overall, 13% in Singapore), compared to 11–22% in the
other regions of the world [3–5]. LTBI forms a large reser-
voir from which new active TB cases develop. Prevention
of transmission and consequent replenishment of the
LTBI reservoir and treatment of LTBI to prevent develop-
ment of active disease are essential if the goals of the
WHO’s End TB are to be achieved [6].
Current tools for diagnosis of LTBI that depend on detec-
tion of an immune response to exogenously-administered
TB antigens - in vivo as the tuberculin skin test (TST), or
ex vivo as an interferon gamma release assay (IGRA) [7] -le is licensed under a Creative Commons Attribution 4.0 International License,
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able to determine whether exposure is recent. A test that
could identify recent exposure may be of value for epi-
demiological research as well as for public health, identify-
ing areas with ongoing high rates of transmission where
active case-finding and infection control measures could be
enhanced to prevent new cases of LTBI. More than half of
prevalent culture positive TB disease is asymptomatic, and
much transmission goes unrecognised [8, 9].
Transcriptome-based signatures have been shown to de-
tect incipient disease in individuals with LTBI that precedes
the onset of clinical disease, indicating the potential of tran-
scriptomics to respond dynamically to subclinical events in
the TB disease spectrum [10–12]. PET-based imaging stud-
ies have demonstrated the existence of early changes,
mainly in lymph nodes, following exposure to TB, [13, 14]
and this suggests that there may be sufficient disease activ-
ity early after exposure to drive a transcriptome response.
In this study, we aimed to determine whether a transcrip-
tome signature can be identified that differentiates individ-
uals with recent TB exposure from those without; to
explore the biological basis of the early exposure signature;
and to examine the relationship between the signature and
relevant clinical and demographic factors.
Methods
Participants and sample collection
We performed a cross-sectional study, comparing gene ex-
pression patterns in three participant groups: a group with
recent TB exposure, without active clinical TB (household
contact group); group without recent TB exposure or active
clinical TB (healthy control group, as a reference to deter-
mine differential gene expression in the TB exposed); and a
group of patients with clinical TB (active TB group; to pro-
vide context for the TB exposure signature).
The household contact group comprised 26 adult con-
tacts of smear-positive index TB cases. They had partici-
pated in a PET-based imaging study conducted at the
National University Hospital (NUH), Singapore from
2013 to 2015, for which the main eligibility criteria were
age over 21 years; residing in the same house as a newly-
diagnosed smear-positive pulmonary TB patient for at
least 1 month prior to start of anti-TB treatment in the
index case [14–16]; receiving no previous treatment for
active TB; having no evidence of active clinical TB; and
no severe uncontrolled diabetes (Supplementary Table 1).
Demographic, clinical and exposure data were collected.
Time from exposure was estimated as the difference be-
tween the date that the index patient first reported
symptoms or began to live in the same household as the
contact, whichever was later, and the date that the blood
was drawn for transcriptome profiling. An IGRA test
was performed (QuantiFERON-TB Gold In-Tube Test,
Qiagen, Hilden, Germany) and repeated afterapproximately 3 months if the initial test was negative or
indeterminate. A whole blood sample was drawn into a
Tempus RNA preservation tube (Thermo Fisher Scien-
tific, Massachusetts, USA), frozen within 2 h of collec-
tion, and stored at − 80 °C until analysis. A PET/MRI
scan was performed, as previously described [14].
The healthy control group comprised 5 volunteers (re-
cruited from a database) who had previously participated
in a PK/PD study at NUH from 2015 to 2016. Partici-
pants with immune deficiency, past history of TB, or
known contact with a TB index case in the previous year
were not enrolled (Supplementary Table 1). Participants
were assessed clinically (symptom questionnaire) to rule
out active TB; demographic and clinical data were col-
lected; an IGRA test was performed; and whole blood
collected in an RNA preservation tube (as above).
The active TB group comprised 14 patients who had a
clinical diagnosis of pulmonary TB (presence of symp-
toms, chest X-ray findings and positive GeneXpert; with
later microbiological confirmation); and less than 1 week
of standard combination treatment (Supplementary
Table 1). They had participated in a PET-based imaging
study at NUH from 2013 to 2015. No IGRA testing was
performed. A whole blood sample was collected in an
RNA preservation tube and stored (as above).
All study protocols were approved by the Singapore
National Healthcare Group Domain Specific Review
Board (NHG DSRB) and all participants gave written in-
formed consent.
Extraction of total RNA from peripheral blood and RNA
sequencing
Samples were thawed, total RNA extracted, and DNAse-
treatment was performed using the column-based Tem-
pus™ Spin RNA Isolation kit (ThermoFisher Scientific,
Massachusetts, USA). RNA was quantified using the
Agilent 2100 Bioanalyzer (Agilent Technologies, Califor-
nia, USA). cDNA libraries were constructed using the
TruSeq total RNA V2 (Illumina, USA). Total RNA was
reverse transcribed into cDNA and ligated with RNA se-
quencing adaptors. RNA sequencing was performed on
Illumina HiSeq Rapid v2 (2x76bp) at the Genome Insti-
tute of Singapore (GIS).
RNASeq data analyses and functional annotation
Sequenced reads (paired-end FASTQ files) were mapped
to the Genome Reference Consortium Human Build 38
release 86 (GRCh38.r86) by using STAR aligner [17].
The aligned reads were counted for each gene using
HTSeq [18]. Sample read counts were adjusted for li-
brary size and normalized using Trimmed Mean of M-
values (TMM) method and multidimensional scaling
plots were used to detect any outlier samples (none
found) using Bioconductor package EdgeR [19].
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exact test in EdgeR. Genes were considered differentially
expressed if they had a false-discovery rate (FDR,
Benjamini-Hochberg) [20] of less than 0.05 and at least a
log2 fold change of ±1.
Gene expression in the household contact group was
compared with the healthy control group to identify dif-
ferentially expressed genes (the “TB exposure signa-
ture”). The nature of the TB exposure signature was
explored further by creating a comprehensive protein
network representation of the proteins associated with
the genes in the signature using Search Tool for the Re-
trieval of Interacting Genes/Proteins (STRING) [21].
Analysis of the associated functional pathways was per-
formed using the GeneOntology (GO) Biological Pro-
cesses on STRING.
The probability of identifying overlap genes in the TB
exposure signature with genes overexpressed in active
TB (compared with the same control group; using the
same FDR thresholds) was tested by exact hypergeo-
metric probability method [22]. The association between
the relative magnitudes of overexpression of genes in the
two groups was assessed by Pearson’s correlation and
the difference by Wilcoxon signed-rank test.
An exposure risk score to quantify the strength of the TB
exposure signature was calculated for each individual in the
household contact group using the normalized gene expres-
sion values of the genes in the TB exposure signature, fol-
lowing an approach described previously [23–25]. Within
the household contact group, the relationship between the
exposure risk score and exposure variables - time from first
exposure (at least 60 days versus less than 60 days), use of
isoniazid prophylaxis at the time of the blood draw, IGRA
positivity, and presence of abnormalities on PET/MRI scan
- was assessed by Mann-Whitney U test.
The area under the curve (AUC) of the receiver oper-
ating characteristic (ROC) curve obtained with the ex-
posure risk score from the TB-exposed household
contacts and TB unexposed healthy control groups was
calculated using a parametric method and the optimal
cut-off for distinguishing between those with and with-
out exposure was determined (ROCR package) [26].
All analyses and figures were generated using the R
software or custom Python scripts.
The sample size for household contacts was determined
by pragmatic considerations of the availability of whole-
blood RNA-preserved samples from previous household
contact studies using PET-MRI performed in our group,
assay costs and the exploratory nature of the study that
did not intend to validate the signature against disease-
progression outcomes; the sample size for the healthy
control group and active TB group were based on similar
pragmatic considerations and experience with other stud-
ies where comparison groups of this size typically allowdetection of differential gene expression in a study group
of interest.
Results
The 26 participants in the household contact group (46%
male, mean age 42 years, 46% Chinese ethnicity) lived in
16 discrete households (ten households contributed one
contact; three households, two contacts; two households,
three contacts; one household, four contacts). They were
studied at a median of 95 (range 0–752) days from esti-
mated first exposure to infection. Thirteen (50%) were
IGRA positive and 4 (15%) had started isoniazid treat-
ment a median of 17 days (range 7–44 days) prior to the
study day; 7 had abnormalities (mainly lymphadenop-
athy) observed on PET/MRI scan, as previously reported
[14]. Participants were otherwise well, without any sig-
nificant underlying medical conditions.
Of the 5 participants in the control group (100% male,
mean age 29 years, 100% Chinese ethnicity), two were
IGRA positive (no recent exposure history). Participants
did not have any significant underlying medical
conditions.
The 14 participants in the active TB group (71% male,
mean age 51 years, 40% Chinese ethnicity) all had drug-
susceptible TB and had been on treatment for a median
of 5 days (range 2–21 days) on the day of the study.
Seven (50%) were smear positive; 7 (50%) had cavitation
on the chest-X-ray; 5 (36%) still had fever and 8 (57%)
cough at the time of the study. Six of the patients had
diabetes mellitus.
We found 186 genes that were differentially expressed
(180 induced, 6 repressed) in household contacts com-
pared to healthy controls (listed in Supplementary
Table 2). Of these 186 genes, 141 (76%) were also differ-
entially expressed in the patients with active TB (versus
healthy controls); there was a moderate association be-
tween the relative magnitude of expression of individual
genes in the two groups (r = 0.66, P < 0.0001) although
overall expression values were lower in the household
contacts (P < 0.00001; Supplementary Figure 1).
Of these 186 genes, 69 have been reported previously
in published human TB-related signatures (Supplemen-
tary Table 3), including 68 previously reported for active
TB (including CD274, IRF7, IFI6) [23–25, 27–35]; 5 in a
126-gene signature of LTBI (ADM, DUSP2, IER3, OSM,
SOCS3; P < 0.011 for overlap) [33]; 4 in a 16-gene signa-
ture of incipient TB in those with LTBI (ANKRD22,
BATF2, SERPING1, SCARF1; P < 0.001 for overlap), [10]
and 2 in a 3-gene signature of incipient TB in TB con-
tacts (BATF2 and SCARF1; P < 0.0001) [36].
Analysis of the proteins associated with all 186 genes
and functional analysis of protein pathways revealed
clusters of proteins from multiple immune response
pathways including the inflammatory response, type I
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pathways (Fig. 1, Supplementary Table 4).
The TB exposure risk score, a composite score calcu-
lated from the values of expression of the 186 genes, did
not differ by time from first exposure (median 17,758
[11,543-31,650] versus 27,005 [10,618-62,190] in those
with exposure onset ≤60 days versus > 60 days prior to
sampling respectively, P = 0.29); by use of isoniazid
prophylaxis (median 38,432 [16,518 – 62,190] versus 22,
758 [10,618 to 44,448] in those taking versus not taking
isoniazid prophylaxis respectively; P = 0.197); or by pres-
ence of lung abnormalities on PET/MRI scan (median
21,400 [15,836 to 43,919] versus 26,510 [10,618 to 62,
190] in those with PET/MRI abnormalities versus no ab-
normalities respectively; P = 0.955).
However, the risk score was higher in contacts who
were IGRA positive (median 28,028 [15,836 – 62,190])
versus IGRA negative (17,469 (10,618 – 44,448]; P =
0.044). The risk score was positive (above the threshold
identified on ROC analysis) in 23 of 26 (88%) contacts,
of whom only 13 (56%) were IGRA positive.
Discussion
We identified a 186-gene signature that can differentiate
people with recent exposure to TB from those without
recent exposure. Transcriptomic signatures have been
shown previously to differentiate active TB from LTBI,
[23, 25, 28, 29, 32, 33, 35, 37] from other infections, [23,
24, 27, 38] and from healthy individuals [25, 27, 28, 30,
32, 33]; to differentiate LTBI from those who are unin-
fected [33, 34, 39]; to identify those at risk of relapse
after treatment for TB disease [40]; and to identify those
with LTBI (including household contacts) who are at
risk of reactivation [10, 11, 25, 36]. However, this is the
first time transcriptomics has been used to differentiate
those with and without recent TB exposure. Our study
adds to the potential applications for transcriptomics-
based testing in an area of special need given the limita-
tions of current diagnostic tools in early TB disease.
This signature is biologically plausible as a signature of
TB exposure. The majority of genes were also found in
our patients with active TB as well as many published
active-TB signatures. Several genes are highly specific
for TB (i.e. CD274, IRF7, IFI6) [27] and others have been
found in signatures indicative of incipient/subclinical TB
(such as BATF2, SCARF1 and SERPING1) [10, 36].
Many of the genes in the signature are non-specific in-
flammatory markers and overexpression might reflect
recent exposure to respiratory or other circulating infec-
tions such as dengue fever that are common in
Singapore. However, this is unlikely to explain our find-
ings because of the strong epidemiological evidence for
recent exposure to a case of smear-positive TB and the
low probability that the majority of household contactswere exposed to viral infections within a short period
prior to blood sampling. Furthermore, analysis of func-
tional protein pathways revealed patterns characteristic of
TB (type I interferon signalling, neutrophil mediated and
inflammation responses) [27] and was consistent with the
evolution of transcriptome signatures in macaques
followed from time of infection (up-regulation of inflam-
mation and interferon pathways was seen during the early
phases post infection) [8]. Although interferon pathways
are also evident in viral infections, the overall pattern of
pathway activation is distinct from that seen in patients
with common respiratory viral infections such as respira-
tory syncytial virus and influenza virus, in which Notch
signalling [41] and ubiquitination signaling pathways [42]
respectively, are distinctive host responses.
Although we did not find a relationship between the
exposure signature and time from exposure, isoniazid
prophylaxis, or the presence of lung PET/MRI abnor-
malities, this may simply reflect the small sample size
and imprecision of estimates. The transcriptome mea-
surements were made at a single timepoint, whereas
studies in macaques indicate a dynamic situation with
progressive attenuation after about 2 months following
exposure [8]. Time from exposure was derived from sub-
jective estimate of the onset of symptoms by the index
case, and exposure likely comprises a series of repeated
exposures over a prolonged period within a household
prior to diagnosis and treatment of the index case. Iso-
niazid effects on bacterial replication may not directly
affect the magnitude of the host immune response if this
evolves independently of the underlying bacterial insult
[43]. The time course of development and resolution of
structural/metabolic changes in the PET/MRI is also un-
known and may not follow the same pattern as those of
the immune or inflammatory processes.
The finding of a higher TB exposure risk score in
IGRA positive contacts provides additional support for
validity of our signature. The positive transcriptome
score in ten participants who were IGRA negative may
reflect clearance of infection by innate immune re-
sponses preventing sufficient TB antigen exposure to
stimulate memory T-cell responses (detected by IGRA).
Alternatively, the T-cell responses could be present but
below the threshold of detection of IGRA; up to 20% of
people with active TB have a negative IGRA, [44] and
the test has substantial variability, even for LTBI [45,
46]. It appears that our transcriptome signature is more
sensitive than IGRA for detecting exposure, consistent
with the finding of expression of a 20-gene signature of
active TB in 26% of persistently IGRA-negative TB con-
tacts (followed for up to 12months after exposure) [25].
A test for recent TB exposure may be of value for TB
control programmes or epidemiological researchers seek-
ing to monitor ongoing TB exposure in the community.
Fig. 1 Protein-protein network of the 186 exposure genes. Each circle represents a protein encoded by a gene. Colors were assigned proteins
that belong to three overrepresented pathways relevant to TB infection. Type 1 interferon signaling pathway (red circles: IFI6, IFITM2, IRF7, ISG15,
OASL, RSAD2, XAF1); Inflammatory response (blue circles: CLEC7A, CLU, CXCL1, CXCL5, FFAR2, FPR1, IL1R1, IL1RN, PF4, PF4V1, PLSCR1, PPBP,
TNFAIP6, TPST10); Neutrophil mediated immunity (green circles: ANXA3, CEACAM3, CXCL1, CXCL5, CXCR1, FCGR2A, FCGR3B, FOLR3, FPR1, GPR97,
PGLYRP1, PPBP, RAP1A, SLPI, TNFAIP6)
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ous antigen at the time of the test (intra-dermal in the case
of the TST or in vitro in the case of IGRA) measure durable
immune responses that are largely independent of thetiming of the original natural exposure [47]. Identifying re-
cent natural (repeat) exposure is especially difficult in a
high-burden setting where the background prevalence of
IGRA or TST positivity is high. In contrast, the in vivo
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sured by a transcriptome test should abate when infection
is cleared and may therefore provide more precise temporal
information of recent exposure, including repeat exposure
in a high-burden setting. Such a test may be of value to
identify environments and populations where there are high
rates (‘hot spots’) of TB exposure and transmission and
where active case-finding and infection control measures
could be enhanced: more than half of prevalent culture
positive TB disease is asymptomatic, and much transmis-
sion goes unrecognised [8, 9].
A transcriptome signature also has the potential to im-
prove the selection of patients for preventive treatment.
Traditional tests have a low positive predictive value for dis-
ease progression: IGRA/TST results did not add signifi-
cantly to a clinical/demographic risk score, [48] and the
excess risk associated with a positive versus negative IGRA/
TST is relatively modest [49]. Our study was not designed
to identify a signature that would predict progression of ac-
tive TB disease; however our signature contained many of
the genes shown to predict disease progression in adoles-
cents in South-Africa and contacts in the UK (two out of
the three reported genes, BATF2 and SCARF1) [10, 36].
Our study lends further support to the potential of this ap-
proach for application in an Asian population.
Limitations of our study include the relatively small
sample size, although it was comparable to other ex-
ploratory studies in the field and proved sufficient to
identify a signature and analyse associated pathways. We
did not collect information on socioeconomic status of
contacts and controls that might partially confound the
findings, although differences would be unlikely to ac-
count for the gene signature in the contacts, given that
it included well known TB-associated genes and protein
pathways. Our signature, although biologically plausible
and consistent with published literature, would require
validation in a large independent cohort prior to wide-
spread use for the detection of recent TB exposure. We
performed one transcriptome measurement per partici-
pant and did not examine evolution of the individual
components of the signature over time. A macaque
study (where the precise timing of exposure is known)
found the greatest differential expression of genes from
pre-infection values occurred between 20 to 56 days
post-infection, and by day 120 following infection the
whole blood signature had returned to baseline values
[8]. The median time from estimated exposure to sam-
pling in our study was 95 days which may have missed
the peak response in some patients. However, a com-
prehensive and systematic description of longitudinal
changes would require more precise knowledge of the
timing of first exposure as well as collection of base-
line samples soon after exposure, both of which are
challenging.Conclusions
We have expanded the scope of application of tran-
scriptomics to identify a signature of recent TB expos-
ure, independent of IGRA testing. Further validation
studies and work to optimise the signature are needed,
followed by validation of a reduced set of genes by RT-
PCR, but this research illustrates the potential for this
approach to be applied for screening to identify areas of
high TB exposure that could benefit from enhanced case
finding and infection control measures; and supports the
potential of transcriptomics to identify more precisely
the individuals who would benefit from preventive
treatment.
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Additional file 1 Supplementary Figure 1. Panel A: Comparison of
the 186 differentially expressed genes in contacts with 792 genes
differentially expressed genes in patients with active TB (both compared
to healthy controls) yielded 141 overlap genes. Panel B: Log2fold change
expression values of the 141 overlap genes for Contacts and active TB
(Wilcoxon signed rank test p < 0.00001). Supplementary Table 1.
Inclusion and exclusion criteria of household contact, active TB and
healthy control groups. Supplementary Table 2. 186 genes from the
comparison of exposed household contacts and healthy control (false
discovery rate < 0.05; log2fold change > 1 or < − 1). Supplementary
Table 3. Genes in the exposure signature in this study that have been
reported in other studies with active TB, latent and incipient TB. Numbers
in cells are log2 fold change relative to comparison group (negative
value represents downregulation); +, gene present but fold change not
reported; −, gene not reported in study; *, IGRA positive vs IGRA-negative
non-exposed controls; **, IGRA/TST positive progressors vs non-
progressors. Supplementary Table 4. All overrepresented GO Biological
Processes of the protein-protein network from STRING analysis. The three
highlighted pathways are represented as colored circles in Fig. 1.
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